Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association: Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010))

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Standard

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association : Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010)). / Wilson, Don P.; Jacobson, Terry A.; Jones, Peter H.; Koschinsky, Marlys L.; McNeal, Catherine J.; Nordestgaard, Børge G.; Orringer, Carl E.

I: Journal of Clinical Lipidology, Bind 16, Nr. 5, 01.09.2022, s. e77-e95.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Harvard

Wilson, DP, Jacobson, TA, Jones, PH, Koschinsky, ML, McNeal, CJ, Nordestgaard, BG & Orringer, CE 2022, 'Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association: Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010))', Journal of Clinical Lipidology, bind 16, nr. 5, s. e77-e95. https://doi.org/10.1016/j.jacl.2022.08.007

APA

Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022). Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association: Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010)). Journal of Clinical Lipidology, 16(5), e77-e95. https://doi.org/10.1016/j.jacl.2022.08.007

Vancouver

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG o.a. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association: Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010)). Journal of Clinical Lipidology. 2022 sep. 1;16(5):e77-e95. https://doi.org/10.1016/j.jacl.2022.08.007

Author

Wilson, Don P. ; Jacobson, Terry A. ; Jones, Peter H. ; Koschinsky, Marlys L. ; McNeal, Catherine J. ; Nordestgaard, Børge G. ; Orringer, Carl E. / Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association : Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010)). I: Journal of Clinical Lipidology. 2022 ; Bind 16, Nr. 5. s. e77-e95.

Bibtex

@article{cb7635d0ca3b415c98d69183eb8ebbd8,
title = "Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association: Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010))",
abstract = "Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.",
keywords = "Atherosclerotic cardiovascular disease, Biomarker, Calcific valvular aortic disease, Cardiovascular risk, Coronary heart disease, Cut points, Lifestyle, Lipoprotein(a), Lp(a), Myocardial infarction, Primary prevention, Scientific statement, Secondary prevention, Stroke, Treatment",
author = "Wilson, {Don P.} and Jacobson, {Terry A.} and Jones, {Peter H.} and Koschinsky, {Marlys L.} and McNeal, {Catherine J.} and Nordestgaard, {B{\o}rge G.} and Orringer, {Carl E.}",
note = "Publisher Copyright: {\textcopyright} 2022 National Lipid Association",
year = "2022",
month = sep,
day = "1",
doi = "10.1016/j.jacl.2022.08.007",
language = "English",
volume = "16",
pages = "e77--e95",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

T2 - Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010))

AU - Wilson, Don P.

AU - Jacobson, Terry A.

AU - Jones, Peter H.

AU - Koschinsky, Marlys L.

AU - McNeal, Catherine J.

AU - Nordestgaard, Børge G.

AU - Orringer, Carl E.

N1 - Publisher Copyright: © 2022 National Lipid Association

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

AB - Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

KW - Atherosclerotic cardiovascular disease

KW - Biomarker

KW - Calcific valvular aortic disease

KW - Cardiovascular risk

KW - Coronary heart disease

KW - Cut points

KW - Lifestyle

KW - Lipoprotein(a)

KW - Lp(a)

KW - Myocardial infarction

KW - Primary prevention

KW - Scientific statement

KW - Secondary prevention

KW - Stroke

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85138571012&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2022.08.007

DO - 10.1016/j.jacl.2022.08.007

M3 - Comment/debate

C2 - 36068139

AN - SCOPUS:85138571012

VL - 16

SP - e77-e95

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 5

ER -

ID: 346781700